On 31 July 2019, a solemn ceremony of launching the first construction phase of the Yusuf Hamied Science and Technology Center will take place at the state enterprise Academpharm of the NAS of Belarus.
The event will be attended by a delegation of the Indian pharmaceutical company Cipla Limited headed by the Chairman of the Board Dr. Yusuf Khwaja Hamied, honorary member of the National Academy of Sciences of Belarus. A delegation from the Indian pharmaceutical company Cipla Limited led by the Chairman of the Board of the company Dr. Yusuf Khwaja Hamied, an honorary member of the National Academy of Sciences of Belarus, will take part in the event.
The delegation from the Indian pharmaceutical company Cipla Limited, headed by Dr. Yusuf Hamied, visits the National Academy of Sciences of Belarus on 28 July – 2 August 2019 to hold talks with the leadership of the NAS of Belarus and discuss promising mechanisms for expanding the interaction between the National Academy of Sciences of Belarus and Indian organizations. Besides, it is planned to discuss the concept of the Yusuf Hamied Science and Technology Center created at the Academpharm and give a lecture to young scientists. The Yusuf Hamid Center is supposed to become a major scientific and technical center for production new medicines on a full cycle: from a scientific concept to manufacturing.
Dr. Yusuf Khwaja Hamied is one of the leading Indian scientists and Chairman of the Cipla Board. He got a PhD in Chemistry at Cambridge. Outside India, Hamied is primarily known for seeking to provide generic AIDS and other drugs to treat poor people in the developing world. On 16 November 2017, during the session of the NASB General Meeting, Dr. Yusuf Hamied was unanimously elected an honorary member of the National Academy of Sciences of Belarus.
* Cipla Limited is an Indian multinational company founded in 1935. Cipla develops more than 1500 medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control and depression and others conditions. Cipla Limited is present in 150 countries around the world. The company is expanding its sphere of influence in the world by creating new more effective medicines and improving the ways of their delivery to the body.